Concord Biotech

1,719.80
+23.20
(1.37%)
Market Cap
17,991.89 Cr
EPS
29.45
PE Ratio
54.34
Dividend Yield
0.52 %
Industry
Healthcare
52 Week High
2,664.00
52 Week Low
1,327.05
PB Ratio
11.15
Debt to Equity
0.01
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,772.50
#1 4,25,282.12
34.87
#1 49,887.20
12.06
#1 9,648
13.77
50.47
5,774.55
1,53,296.16
72.74
8,184.00
0.89
1,600
#1 64.53
46.20
1,499.10
1,21,069.56
23.51
26,520.70
14.17
4,155
47.38
45.27
3,244.20
1,09,798.47
58.33
10,785.70
11.59
1,656
13.54
55.87
2,425.00
1,00,050.29
48.93
10,615.60
19.57
1,942
-16.38
55.89
1,156.95
96,542.31
#1 17.86
28,905.40
12.36
5,578
1.69
45.11
2,087.20
95,289.23
31.98
20,141.50
#1 19.94
1,936
38.82
47.61
908.00
91,366.05
19.78
19,831.50
13.82
3,831
29.92
44.76
1,177.45
68,386.49
19.09
29,559.20
17.55
3,169
-10.04
52.27
29,850.00
63,429.17
47.09
6,097.20
10.80
1,201
16.01
44.78

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
18.26 %
Net Income Growth
28.32 %
Cash Flow Change
7.91 %
ROE
8.44 %
ROCE
7.81 %
EBITDA Margin (Avg.)
3.94 %

Quarterly Financial Results

Quarterly Financials
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
195
165
250
285
208
271
252
330
228
320
261
Expenses
116
122
131
146
123
147
135
187
135
177
146
EBITDA
79
44
119
139
85
124
117
143
93
144
115
Operating Profit %
36 %
24 %
46 %
47 %
37 %
44 %
44 %
41 %
38 %
43 %
40 %
Depreciation
14
13
14
14
13
13
14
14
13
13
13
Interest
1
1
1
2
1
1
1
1
0
0
0
Profit Before Tax
64
30
105
124
71
110
103
129
80
130
101
Tax
15
8
27
32
17
29
26
34
20
35
25
Net Profit
49
22
77
92
55
81
78
95
60
96
76
EPS in ₹
4.71
2.10
7.40
8.75
5.21
7.74
7.41
9.08
5.70
9.15
7.26

Balance Sheet

Balance Sheet
2020
2022
2023
2024
Total Assets
941
1,313
1,514
1,701
Fixed Assets
240
573
593
575
Current Assets
539
633
728
896
Capital Work in Progress
141
74
173
212
Investments
199
74
137
246
Other Assets
361
592
611
668
Total Liabilities
941
1,313
1,514
1,701
Current Liabilities
115
155
192
142
Non Current Liabilities
55
54
32
32
Total Equity
770
1,103
1,290
1,527
Reserve & Surplus
761
1,094
1,280
1,516
Share Capital
10
10
11
11

Cash Flow

Cash Flow
2020
2022
2023
2024
Net Cash Flow
-1
-5
3
12
Investing Activities
-114
-112
-158
-155
Operating Activities
155
208
246
266
Financing Activities
-43
-100
-85
-99

Share Holding

% Holding
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
44.08 %
FIIs
0.00 %
7.30 %
0.00 %
6.48 %
7.11 %
8.10 %
8.33 %
DIIs
4.89 %
8.18 %
8.13 %
8.46 %
10.40 %
9.89 %
9.66 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
13.33 %
6.78 %
6.76 %
7.08 %
7.64 %
7.33 %
7.33 %
Others
37.69 %
33.66 %
41.03 %
33.90 %
30.76 %
30.61 %
30.59 %
No of Share Holders
3,77,572
1,00,927
87,486
83,296
80,737
84,298
82,004

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.83 8.75 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.52 0.00

Corporate Action

Announcements

Commencement Of Commercial Production At Unit-4 Valthera9 days ago
Closure of Trading WindowMar 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Board Meeting Outcome for TO Make INVESTMENT IN M/S CLEAN MAX EVERGLADES PVT LTD FOR INSTALLATION OF HYBRID RENEWABLE ENERGY PLANTMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 21, 2025
Intimation About Completion Of Inspection By Ministry Of Food And Drug Safety (MFDS) At Dholka (Unit I) Of The Company.Feb 20, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 14, 2025
Integrated Filing (Financial)Feb 13, 2025
Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Board Meeting Outcome for Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2025
Board Meeting Intimation for Financial ResultsJan 24, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJan 16, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 11, 2025
Announcement under Regulation 30 (LODR)-AcquisitionDec 12, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2024
Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 11, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held Today, November 11, 2024 - Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Board Meeting Intimation for Board Meeting Intimation For Approve The Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Closure of Trading WindowSep 25, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 24, 2024
Clarification On Price MovementSep 24, 2024
Clarification sought from Concord Biotech LtdSep 23, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 30, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationAug 10, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 10, 2024
Financial Results For 30/06/2024Aug 09, 2024
Board Meeting Outcome for Outcomes Of Board Meeting For The Unaudited Financials Results For The First Quarter Ended On June 30, 2024Aug 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2024
Board Meeting Intimation for Approve The Standalone And Consolidated Unaudited Financial Results For The First Quarter Ended June 30, 2024Jul 31, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 09, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportJul 02, 2024

Technical Indicators

RSI(14)
Neutral
47.59
ATR(14)
Less Volatile
89.64
STOCH(9,6)
Neutral
60.86
STOCH RSI(14)
Neutral
75.79
MACD(12,26)
Bullish
19.69
ADX(14)
Weak Trend
17.37
UO(9)
Bearish
49.95
ROC(12)
Uptrend And Accelerating
2.88
WillR(14)
Neutral
-28.47

About Concord Biotech

Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Listing Date
18 Aug, 2023(1 Years, 16 days)
Chairperson NameSUDHIR JAIRAM VAID